Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
CuraGen Evaluates Strategic Options
by Michael McCoy
February 23, 2009
| A version of this story appeared in
Volume 87, Issue 8
Saying its stock price doesn't reflect its intrinsic value, biotech firm CuraGen is evaluating its strategic options. CuraGen's lead product is CR011, a monoclonal antibody-drug conjugate in Phase II clinical trials for the treatment of metastatic melanoma. According to Chairman Robert E. Patricelli, CuraGen's alternatives include selling or licensing CR011, acquiring additional assets, and selling the company. CuraGen has already hired transaction advisory firm JSB-Partners to identify potential buyers of CR011.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter